Samsung Bioepis, Teva sign global pact for up to six biosimilar candidates
Bitget2026/10/01 08:30- Samsung EPIS Holdings unit Samsung Bioepis signed a global license, development, and commercialization deal with Teva for up to six biosimilars.
- Samsung Bioepis to develop, file, and manufacture; Teva to commercialize in the US, Europe, Canada, with an option to add territories.
- Initial confirmed candidates include SB41 referencing AstraZeneca’s Fasenra, SB44 referencing Novartis’ Ilaris.
- Deal expands an existing partnership that already commercialized EPYSQLI in the US, with OPUVIZ added for Canada.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
